Qiagen NV

Type: Company
Name: Qiagen NV
Nationality: Netherlands
Web Address: http://www.qiagen.com/
Fact Sheet: Fact Sheet for Qiagen NV
First reported 35 mins ago - Updated 35 mins ago - 1 reports

Qiagen licenses biomarker for blood disorder diagnosis

:06 in Scientific Company News Qiagen has acquired an exclusive worldwide license to a promising biomarker that could aid the diagnosis of a group of blood disorders. The biomarker calreticulin (CALR) has been found to present mutations in an estimated ... [Published Zenopa - 35 mins ago]
First reported 7 hours ago - Updated 3 hours ago - 6 reports

QIAGEN Announces Facility Changes

QIAGEN today announced plans to combine its three Maryland sites into two campuses and invest an additional $10 million to accommodate expected future growth. The company will close its current site at Gaithersburg, Maryland and move the Gaithersburg ... [Published PharmaceuticalProcessing - 3 hours ago]
First reported 7 hours ago - Updated 6 hours ago - 2 reports

Research and Markets: Global Companion Diagnostics Market 2014-2018 with Abbott Laboratories, Agilent Technologies, bioMrieux SA, Qiagen N.V. & Roche Holding Dominating

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/84cgmr/global_companion) has announced the addition of the "Global Companion Diagnostics Market 2014-2018" report to their offering. The Global Companion Diagnostics ... [Published Business Wire Health News - 6 hours ago]
First reported 14 hours ago - Updated 9 hours ago - 2 reports

Qiagen: Why I Prefer Waiting On The Sidelines

By Andy Batts :Netherlands-based Qiagen N.V. ( QGEN ) is a leading global provider of sample and assay technologies. The company aims to accelerate growth in 2014 primarily by boosting the global adoption of its QIAsymphony platform and establishing the ... [Published BioPortfolio - 9 hours ago]
First reported 11 hours ago - Updated 11 hours ago - 1 reports

Qiagen shifting employees from Gaithersburg into expanded manufacturing space in Germantown

Qiagen SciencesNew manufacturing lines in a new addition to Qiagen Sciences in Germantown will enable the company to make products to test for latent tuberculosis there.advertisementDutch biotech Qiagen Sciences will soon expand its operations in Montgomery ... [Published Gazette.net - 11 hours ago]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Qiagen (QGEN) Showing Support Near $19.78

A covered call identified by MarketIntelligececenter.com's patented algorithm on Qiagen NV (QGEN) could yield about 5.76% (17.10% annualized, for comparison purposes only) in 123 days. Pair a long position in the stock with the Aug. '14 $20.00 call for ... [Published MarketIntelligenceCenter.com - Apr 15 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Qiagen licenses myeloproliferative neoplasm biomarker from CeMM

The Austrian Academy of Sciences’ CeMM Research Center for Molecular Medicine licensed Qiagen NV (consumables, lab instruments, and detection technologies) exclusive global rights to calreticulin, a potential biomarker for use in diagnostics and ne.. ... [Published BioPortfolio - Apr 15 2014]
Entities: Qiagen NV, Biomarker, Tumor
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Opportunities and Challenges of Doing Business in Companion Diagnostics

For my occasional series of blogs examining various facets of the companion diagnostics market, I asked some of the major IVD manufacturers to share their thoughts and opinions on the current opportunities and challenges in companion diagnostics. The ... [Published Medical Design Technology - Apr 14 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Qiagen acquires biomarker for blood disorders

Qiagen has acquired an exclusive worldwide licence to the biomarker calreticulin (CALR), whose mutations are found in an estimated 15% of cases of myeloproliferative neoplasms (MPNs) - a group of blood disorders involving overproduction of blood cell ... [Published LabOnline - Apr 14 2014]
First reported Apr 11 2014 - Updated Apr 12 2014 - 4 reports

QIAGEN licenses CALR biomarker from CeMM Vienna

HILDEN, Germany & VIENNA, Austria—QIAGEN N.V. has announced that it has secured an exclusive, worldwide license to the biomarker calreticulin (CALR) from . Scientists at CeMM Vienna led the team that discovered the presence of the CALR protein in myeloproliferative ... [Published Drug Discovery News - Apr 12 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 2 reports

QIAGEN Down 9.4% Since SmarTrend Downtrend Call (QGEN)

Written on Fri, 04/11/2014 - 12:47pmBy Amy SchwartzSmarTrend identified a Downtrend for QIAGEN ( NASDAQ:QGEN ) on January 29th, 2014 at $22.71. In approximately 2 months, QIAGEN has returned 9.42% as of today's recent price of $20.57.In the past 52 weeks, ... [Published Comtex SmarTrend - Apr 11 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 2 reports

QIAGEN Adds Promising New Biomarker to Pipeline of Personalized Healthcare Assays to Improve Diagnosis of Blood Disorders

Hilden, Germany And Vienna (ots/PRNewswire) - - Reliable diagnostic tools under development for mutations of calreticulin (CALR) are expected to benefit patients with blood disorders known as myeloproliferative neoplasms - QIAGEN acquired exclusive worldwide ... [Published PRESSEMITTEILUNGEN - Apr 10 2014]

Quotes

...Peer Schatz, chief executive officer of Qiagen, said: "Together, the JAK2 and CALR biomarkers give us the ability to deliver personalised insights regarding diagnosis, prognosis and disease management for patients with myeloprofilerative disorders." This comes in the same week that the company announced plans to expand and upgrade its US Germantown facilities, while also consolidating its Maryland...
"Concise Analysis of the International Molecular Diagnostics in Infectious Disease Testing" , describes the specific segment of the in vitro diagnostics market known as molecular diagnostics testing for infectious disease...
"At Germantown, we are creating a global focus on molecular diagnostics for disease prevention, including women's health and tuberculosis, by placing our R&D teams on the same campus with marketing and manufacturing for those products" said Douglas Liu, senior vice president of operations, in the statement
...our R&D teams on the same campus with marketing and manufacturing for those products," said Douglas Liu , Senior Vice President, Operations. "QIAGEN's investment of $10 million in the Maryland locations, added to our investment over the past two years, brings our total recent commitment to $50 million . This upgrade will prepare us for expected growth in the coming years, including moving additional support to Maryland for several rapidly growing product lines."

More Content

All (366) | News (258) | Reports (1) | Blogs (26) | Audio/Video (0) | Fact Sheets (3) | Press Releases (78)
sort by: Date | Relevance
Qiagen licenses biomarker for blood disorder di... [Published Zenopa - 35 mins ago]
Concise Analysis of the International Molecular... [Published Yahoo! Finance - 1 hour ago]
GI Research Improving Quality of Life in Rectal... [Published Oncology Times - 1 hour ago]
QIAGEN Announces Facility Changes [Published PharmaceuticalProcessing - 3 hours ago]
Qiagen begins consolidating Maryland operations... [Published Washington Post - 4 hours ago]
Qiagen puts up $10M to boost its diagnostics ma... [Published FierceMedicalDevices - 4 hours ago]
Qiagen to depart old Digene HQ, expand two othe... [Published Washington Business Journal - 5 hours ago]
Potential Qiagen (QGEN) Trade Has 6.25% Downsid... [Published MarketIntelligenceCenter.com - 5 hours ago]
Research and Markets: Global Companion Diagnost... [Published Business Wire Health News - 6 hours ago]
Global Companion Diagnostics Market 2014-2018 w... [Published Individual.com - 7 hours ago]
QIAGEN expands and upgrades Germantown faciliti... [Published Michigan Live - 7 hours ago]
QIAGEN expands and upgrades Germantown faciliti... [Published PR Newswire: Health - 7 hours ago]
Qiagen: Why I Prefer Waiting On The Sidelines [Published BioPortfolio - 9 hours ago]
Qiagen shifting employees from Gaithersburg int... [Published Gazette.net - 11 hours ago]
Qiagen: Why I Prefer Waiting On The Sidelines [Published Seeking Alpha - 14 hours ago]
Hottest Healthcare Stocks Now – CNMD EXAS ACAD ... [Published InvestorPlace.com - 18 hours ago]
Global Diversification at the Harsh Sea-Land In... [Published PLoS medicine - 19 hours ago]
Nucleic Acid Isolation and Purification Market ... [Published TickerTech.com - Apr 15 2014]
The Global Market for Biomarkers: Concise Analy... [Published Individual.com - Apr 15 2014]
Qiagen (QGEN) Showing Support Near $19.78 [Published MarketIntelligenceCenter.com - Apr 15 2014]
Qiagen licenses myeloproliferative neoplasm bio... [Published BioPortfolio - Apr 15 2014]
Glucagon Stimulates Hepatic FGF21 Secretion thr... [Published PLoS medicine - Apr 15 2014]
Adventitial Delivery of Lentivirus-shRNA-ADAMTS... [Published PLoS medicine - Apr 14 2014]
Combination of Liposomal CpG Oligodeoxynucleoti... [Published PLoS medicine - Apr 14 2014]
Opportunities and Challenges of Doing Business ... [Published Medical Design Technology - Apr 14 2014]
Potential Qiagen (QGEN) Trade Targets 6.21% Return [Published MarketIntelligenceCenter.com - Apr 14 2014]
Research and Markets: Global Companion Diagnost... [Published BusinessWeek - Apr 14 2014]
Global Companion Diagnostics (CDx) Market 2013-... [Published Individual.com - Apr 14 2014]
Lab Automation Market (Automated Liquid Handlin... [Published Individual.com - Apr 14 2014]
Qiagen acquires biomarker for blood disorders [Published LabOnline - Apr 14 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Potential Qiagen (QGEN) Trade Has 6.25% Downsid... [Published MarketIntelligenceCenter.com - 5 hours ago]
Option-trade picking algorithms patented by MarketIntelligenceCenter.com found a trading opportunity with Qiagen NV (QGEN) that should provide a 6.61% return in just 122 days. Sell one Aug. '14 call at the $20.00 level for each 100 shares of Qiagen for ...
Research and Markets: Global Companion Diagnost... [Published Business Wire Health News - 6 hours ago]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/84cgmr/global_companion) has announced the addition of the "Global Companion Diagnostics Market 2014-2018" report to their offering. The Global Companion Diagnostics ...
QIAGEN expands and upgrades Germantown faciliti... [Published PR Newswire: Health - 7 hours ago]
GERMANTOWN, Md., April 16, 2014 /PRNewswire/ --Investment of $10 million in Germantown and Frederick campuses brings QIAGEN's total recent commitment in Maryland to $50 millionGermantown campus becomes state-of-the-art research, manufacturing and office ...
Qiagen (QGEN) Showing Support Near $19.78 [Published MarketIntelligenceCenter.com - Apr 15 2014]
A covered call identified by MarketIntelligececenter.com's patented algorithm on Qiagen NV (QGEN) could yield about 5.76% (17.10% annualized, for comparison purposes only) in 123 days. Pair a long position in the stock with the Aug. '14 $20.00 call for ...
Potential Qiagen (QGEN) Trade Targets 6.21% Return [Published MarketIntelligenceCenter.com - Apr 14 2014]
MarketIntelligenceCenter.com's patented trade-picking algorithms have identified an attractive covered-call trade on Qiagen NV (QGEN). Look at the Aug. '14 $20.00 covered call for a net debit in the $18.83 area. This trade has a duration of 124 days. ...
1 2 3 4 5 6

Press Releases

sort by: Date | Relevance
QIAGEN N.V. to Report First Quarter 2014 Result... [Published GlobeNewswire: Advertising News - Apr 09 2014]
DGAP-CMS: QIAGEN N.V.: Release of a capital mar... [Published GlobeNewswire: Advertising News - Apr 09 2014]
DGAP-DD: QIAGEN N.V. english [Published GlobeNewswire: Advertising News - Apr 03 2014]
DGAP-DD: QIAGEN N.V. english [Published GlobeNewswire: Advertising News - Apr 03 2014]
DGAP-CMS: QIAGEN N.V.: Release of a capital mar... [Published GlobeNewswire: Advertising News - Mar 31 2014]
1 2 3 4 5 6 7 8 9 10 ...
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.